Quantum BioPharma posts stronger Q3 balance sheet and launches Lucid‑MS Phase 2 trial
Quantum BioPharma released its unaudited third‑quarter 2026 results, showing cash and digital assets of $12.22 million and shareholders’ equity of $9.77 million, a 91 % increase from the end of 2025. Operating expenses fell 24 % year‑over‑year and the nine‑month net loss narrowed to $17.32 million. After quarter‑end the company signed a Study Start‑Up Agreement with Thermo Fisher Scientific to begin a Phase 2 trial of its Lucid‑MS candidate in progressive multiple sclerosis, following FDA clearance of the IND in August 2026.
Why it matters
The stronger liquidity and equity position give the company enough resources to fund operations for the next twelve months, according to management. The initiation of the Phase 2 trial moves Lucid‑MS closer to potential market approval, which could create future revenue streams if the trial succeeds.
Key facts
- 1Cash and cash equivalents were about US$3.56 million as of September 30 2026. globenewswire.com
- 2Digital assets were about US$8.66 million as of September 30 2026. globenewswire.com
- 3Combined cash and digital assets totaled approximately US$12.22 million, up from US$4.12 million at December 31 2025. globenewswire.com
- 4Total shareholders’ equity rose to US$9.77 million, a 91 % increase from US$5.10 million at December 31 2025. globenewswire.com
- 5Total assets grew to US$17.33 million, up from US$11.16 million at year‑end 2025. globenewswire.com
- 6Operating expenses for the quarter decreased 24 % year‑over‑year to US$3.56 million. globenewswire.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.